epratuzumab

Type: Product

Name: epratuzumab

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Mum of Sunderland leukaemia boy welcomes children’s cancer trial

THE mum of an 11-year-old boy battling leukaemia today welcomed the news researchers in the North East are to take part in a pioneering clinical trial on children?s cancer. The Northern Institute for Cancer Research has been selected to be a part of the ... [Published Sunderland Echo - May 17 2013]

Entities: Leukaemia, Acute Lymphoblastic Leukemia, Cancer, Cancer Research

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Immunomedics' CEO Discusses F3Q13 Results - Earnings Call Transcript

10:00 AM ETOperatorGood morning, ladies and gentlemen, and thank you for standing-by. Welcome to Immunomedics, Incorporated Third Quarter Fiscal 2013 Financial Results Conference Call. As a reminder, this call is being recorded. Today is Thursday, May, ... [Published Seeking Alpha - May 09 2013]

Entities: Antibody, Systemic Lupus Erythematosus, epratuzumab, SN-38

First reported May 08 2013 - Updated May 09 2013 - 3 reports

Financial Industry Regulatory Authority

Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments GlobeNewswire

(GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial ... [Published Yahoo! Finance - May 08 2013]

Entities: Immunomedics Inc, Fiscal Year, Financial Industry Regulatory Authority

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Today's News: North East team set to lead clinical trial on children's cancer

The Newcastle-based Northern Institute for Cancer Research has been selected to be a part of the world?s largest study for treatment of childhood relapsed Acute Lymphoblastic Leukaemia (ALL).A total of 19 countries will make up the consortium and scientists ... [Published The Journal - May 08 2013]

Entities: Acute Lymphoblastic Leukemia, Cancer Research, Clinical trials

First reported Apr 25 2013 - Updated Apr 25 2013 - 2 reports

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2013 Financial Results

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it will host a conference ... [Published Individual.com - Apr 25 2013]

Entities: Immunomedics Inc, Antibody, Cancer, Clinical trials, epratuzumab

First reported Apr 10 2013 - Updated Apr 10 2013 - 2 reports

IMMUNOMEDICS, INC. : IMMUNOMEDICS DEVELOPS T-CELL REDIRECTING BISPECIFIC ANTIBODIES AS POTENTIAL THERAPEUTICS FOR SOLID AND LIQUID TUMORS

300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤ Fax (973) 605-8282 based products for the targeted treatment of cancer, autoimmune and other serious diseases,today announced the development of novel T-cell redirecting agents ... [Published 4 Traders - Apr 10 2013]

Entities: Immunomedics Inc, epratuzumab, Antibody, Therapeutics

First reported Apr 01 2013 - Updated Apr 01 2013 - 1 reports

Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced ... [Published Stockwatch - Apr 01 2013]

Entities: Immunomedics Inc, Financial Industry Regulatory Authority, Arbitration

First reported Jan 29 2013 - Updated Jan 29 2013 - 1 reports

Algeta oncology research program to evaluate targeted thorium conjugate

Algeta will assess the potential of targeted thorium conjugate (TTC), a combination of its thorium-227 alpha-pharmaceutical payload and Immunomedics' anti-CD22 monoclonal antibody (epratuzumab), through a new oncology research program. ... [Published PBR - News - Jan 29 2013]

Entities: Algeta ASA, Thorium, epratuzumab, Thorium-227, Immunomedics Inc

Quotes

...launch the product, with Bayer, if approved by the US FoodFood and Drug Administration later this year," said Andrew Kay, Algeta's President & CEO. "We are also making good progress with the development of our Targeted Thorium Conjugate (TTC) pipeline and look forward to the results of further preclinical evaluations which will guide our choice of which TTC candidate to advance into clinical trials next year."

Algeta ASA: Algeta results for the first quarter 2013 [Published FinanzNachrichten.de - May 15 2013]

...as well as maintain our operations according to plan," commented Gerard G Gorman, Senior Vice President Finance and Chief Financial Officer. "Clivatuzumab remains our top priority in our clinical pipeline and we look forward to reporting results from the Phase Ib study at upcoming medical conferences" Mr. Gorman added

Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments GlobeN ... [Published Yahoo! Finance - May 08 2013]

In addition, IBC Pharmaceuticals, Inc., the Company's majority-owned subsidiary, has received notice that additional claims for the patent family, "Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo" will issue as U S patent no. 8,435,540 today

Immunomedics Announces Three New Patent Awards [Published Nasdaq - May 07 2013]

...of 2013 shows solid growth of our core medicines, Cimzia®, Vimpat® and Neupro® as well as in emerging markets", said Roch Doliveux, CEO of UCB. "At the same time as we are facing the remaining post exclusivity impacts on Keppra® we are facing strong seasonal effects due to the continued cold winter, affecting our allergy franchise. We are pleased with our pipeline performance, which includes positive phase 3 results in the U S with Vimpat® to treat epilepsy in monotherapy and a new project joining our pipeline - tozadenant in Parkinsons' disease."

UCB : Slow Start but Outlook 2013 and Growth Prospects Confirmed [Published 4 Traders - Apr 25 2013]

More Content

sort by: Date \| Relevance
Mum of Sunderland leukaemia boy welcomes childr... [Published Sunderland Echo - May 17 2013]
Algeta ASA: Algeta results for the first quarte... [Published FinanzNachrichten.de - May 15 2013]
Immunomedics' CEO Discusses F3Q13 Results - Ear... [Published Seeking Alpha - May 09 2013]
Immunomedics Announces Third Quarter Fiscal 201... [Published Yahoo! Finance - May 08 2013]
Immunomedics Announces Third Quarter Fiscal 201... [Published Individual.com - May 08 2013]
Immunomedics Announces Third Quarter Fiscal 201... [Published Morningstar.com - May 08 2013]
Today's News: North East team set to lead clini... [Published The Journal - May 08 2013]
Immunomedics Announces Three New Patent Awards [Published Nasdaq - May 07 2013]
Immunomedics Announces Conference Call and Webc... [Published Individual.com - Apr 25 2013]
Immunomedics Announces Conference Call and Webc... [Published Zecco - Apr 25 2013]
UCB : Slow Start but Outlook 2013 and Growth Pr... [Published 4 Traders - Apr 25 2013]
Report Published: "Lupus Erythematosus - Pipeli... [Published Live-PR.com - Apr 21 2013]
Three Biotech Stocks With Low Price But Great P... [Published Seeking Alpha - Apr 16 2013]
IMMUNOMEDICS DEVELOPS T-CELL REDIRECTING BISPEC... [Published World News Network - Apr 10 2013]
IMMUNOMEDICS, INC. : IMMUNOMEDICS DEVELOPS T-CE... [Published 4 Traders - Apr 10 2013]
Immunomedics Develops T-Cell Redirecting Bispec... [Published Nasdaq - Apr 10 2013]
IMMUNOMEDICS, INC.: Immunomedics reports first ... [Published 4 Traders - Apr 09 2013]
Immunomedics Reports First Results of Labetuzum... [Published Equities.com - Apr 09 2013]
Immunomedics Reports First Results of Labetuzum... [Published Zecco - Apr 09 2013]
Immunomedics Announces Clivatuzumab-Based Blood... [Published Stockwatch - Apr 08 2013]
For the Treatment of Lupus, the Emerging Therap... [Published PR Newswire: Health - Apr 02 2013]
Immunomedics Settles Finra Arbitration Proceedi... [Published Stockwatch - Apr 01 2013]
Deals Of The Weeks Wonders If A Biopharma Super... [Published The IN VIVO Blog - Feb 01 2013]
Algeta oncology research program to evaluate ta... [Published PBR - News - Jan 29 2013]
Immunomedics in Collaboration With Algeta to Ev... [Published GlobeNewswire: Acquisitions News - Jan 28 2013]
Addition of Epratuzumab to Combination Chemothe... [Published GlobeNewswire: Advertising News - Dec 10 2012]
Immunomedics to Present at 2012 UBS Global Life... [Published GlobeNewswire - Sep 13 2012]
Immunomedics to Present at 2012 Wedbush PacGrow... [Published GlobeNewswire - Aug 07 2012]